Lipella Pharmaceuticals Inc (LIPO): Price-to-Revenue Ratio

Symbol and logo of brand Lipella (LIPO)

Lipella Pharmaceuticals operations are protected by US regulations, which minimizes trade conflict risks. The company is developing oral therapies for genitourinary system pathologies, leveraging patent protection. The implementation of ESG standards and emissions scrubbing optimize laboratory operations. The P/S time series allows for the correlation of revenue market value with debt, while 7.30 shows the current volume of this metric.

Lipella Pharma (LIPO): Price-to-Revenue Ratio from 04/28/2023 to 07/19/2025

Metric breakdowns and analytics for Lipella (LIPO)

- share price and consensus valuation forecast:
Price Performance Chart lipella.com|LIPO - Price Target Chart
- stock exchange capitalization data:
Market Value Lipella|LIPO - Enterprise Value
- issuer book value statistics:
Net Assets per Share Lipella Pharmaceuticals|LIPO - Company Book Value|Market Capitalization to Net Assets lipella.com|LIPO - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Lipella Pharmaceuticals|LIPO - Long-Term Debt to Equity|Short-Term Debt to Equity Lipella Pharma|LIPO - Company Debts|Debt to Book Capitalization Ratio Lipella|LIPO - Company Long-Term Debts|Company Short-Term Debts Lipella Pharmaceuticals|Intermediate Coverage Ratio lipella.com
- net income and valuation ratios data:
LIPO - Company Net Income|Forward Earnings Lipella Pharmaceuticals|LIPO - P/E Multiple|Future Price to Earnings Multiple Lipella Pharmaceuticals Inc|LIPO - PEG Multiple|EV/EBITDA Multiple Lipella|LIPO - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Lipella Pharmaceuticals|LIPO - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months lipella.com|LIPO - Earnings growth in current year|Earnings growth forecast for next year Lipella Pharmaceuticals
- total revenue and sales volume data:
LIPO - Revenue and Sales Volume|Company Future Sales Volume lipella.com|LIPO - P/S Multiple|Market Cap to Future Revenue Ratio Lipella
Fundamental company analysis:lipella.com LIPO
Mass-produced product of Lipella Pharma

The P/S ratio determines the market value of a business relative to its annual turnover, allowing for an assessment of the premium paid for each unit of revenue. For Lipella Pharmaceuticals (LIPO), which has fully outsourced its production and research to external contractors, this indicator is critically important, as current P/S dynamics reveal a speculative gap between capitalization and actual sales in the absence of in-house capacities.

Competing companies

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|Verona Pharma PLC - Price-to-Revenue Ratio|Jyong Biotech Corp - P/S Multiple|Price-to-Revenue Coefficient Ligand Corp LGND|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|Price-to-Sales Ratio PRGO (perrigo.com)|ALVO (Alvotech SA) - P/S Multiple|Price to Sales Liquidia Corp LQDA|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|Price-to-Revenue Ratio ANIP (ANI Pharmaceuticals Corp)|Price-to-Revenue Ratio MannKind Corporation MNKD|amphastar.com - Price-to-Revenue Ratio|Pacira BioSciences, Inc. - P/S Multiple|SPRY - P/S Multiple|TBPH (Theravance) - Market Cap to Revenue|Aquestive Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio scPharmaceuticals, Inc.|Tectonic - Price-to-Sales Ratio|P/S Multiple TNXP|SXTC (sxtchina.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|P/S Multiple BioHarvest Sciences Inc BHST|EXOZ - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ORMP (Oramed Pharmaceuticals)|enterabio.com (ENTX) - Price-to-Revenue Ratio|Market Cap to Revenue MindWalk Holdings, Inc.|ABVC (ABVC BioPharma Inc) - P/S Multiple|P/S Multiple Cumberland Corp|P/S Multiple QNTM|Market Cap to Revenue fibrogen.com FGEN|P/S Multiple TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings (RANI) - Price to Sales|SNYR: Market Cap to Revenue|RLYB - P/S Multiple|LEXX (lexariabioscience.com) - Market Cap to Revenue|PULM: Market Cap to Sales Volume|PTHL (Pheton Holdings Limited) - P/S Multiple|Aptorum (APM) - Price-to-Revenue Coefficient|P/S Multiple LYRA|Market Cap to Revenue Impact BioMedical, Inc. IBO|P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|P/S Multiple cbdMD Inc. YCBD|PRFX - Price-to-Revenue Ratio|CYTO: Price-to-Revenue Ratio|Optinose (OPTN) - Price-to-Revenue Ratio|PIRS - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Procaps Group S.A.|Price-to-Revenue Ratio PTPI|P/S Multiple QLI|Price-to-Revenue Coefficient Acelyrin Inc.|Price-to-Revenue Ratio TFF Pharma TFFP